Sanjay Rai

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella, Siddharth Reddy, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 365 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · The Lancet · 2021 · 362 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

CONGENITAL CYTOMEGALOVIRUS INFECTION IN A HIGHLY SEROPOSITIVE SEMI-URBAN POPULATION IN INDIA

Lalit Dar, Sunil Pati, A. Raj Kumar Patro et al. · The Pediatric Infectious Disease Journal · 2008 · 88 citations

Medicine, Infectious Diseases, Pediatrics +10

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · medRxiv · 2021 · 80 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report

Raches Ella, Siddharth Reddy, Harsh Jogdand et al. · medRxiv · 2020 · 38 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17